<?xml version='1.0' encoding='utf-8'?>
<document id="24147143"><sentence text="Prevalence of the prescription of potentially interacting drugs." /><sentence text="The use of multiple medications is becoming more common, with a correspondingly increased risk of untoward effects and drug-related morbidity and mortality" /><sentence text=" We aimed at estimating the prevalence of prescription of relevant potentially interacting drugs and at evaluating possible predictors of potentially interacting drug exposure" /><sentence text=" We retrospectively analyzed data on prescriptions dispensed from January 2004 to August 2005 to individuals of two Italian regions with a population of almost 2" /><sentence text="1 million individuals" /><sentence text=" We identified 27 pairs of potentially interacting drugs by examining clinical relevance, documentation, and volume of use in Italy" /><sentence text=" Subjects who received at least one prescription of both drugs were selected" /><sentence text=" Co-prescribing denotes &quot;two prescriptions in the same day&quot;, and concomitant medication &quot;the prescription of two drugs with overlapping coverage&quot;" /><sentence text=" A logistic regression analysis was conducted to examine the predictors of potential Drug-Drug Interaction (pDDIs)" /><sentence text=" 957,553 subjects (45" /><sentence text="3% of study population) were exposed to at least one of the drugs/classes of the 27 pairs" /><sentence text=" Overall, pDDIs occurred 2,465,819 times" /><sentence text=" The highest rates of concomitant prescription and of co-prescription were for ACE inhibitors+NSAIDs (6,253 and 4,621/100,000 plan participants)" /><sentence text=" Considering concomitance, the male/female ratio was &lt;1 in 17/27 pairs (from 0" /><sentence text="31 for NSAIDs-ASA+SSRI to 0" /><sentence text="74 for omeprazole+clopidogrel)" /><sentence text=" The mean age was lowest for methotrexate pairs (+omeprazole, 59"><entity charOffset="29-41" id="DDI-PubMed.24147143.s17.e0" text="methotrexate" /><entity charOffset="49-60" id="DDI-PubMed.24147143.s17.e1" text="+omeprazole" /><pair ddi="false" e1="DDI-PubMed.24147143.s17.e0" e2="DDI-PubMed.24147143.s17.e0" /><pair ddi="false" e1="DDI-PubMed.24147143.s17.e0" e2="DDI-PubMed.24147143.s17.e1" /></sentence><sentence text="9 years; +NSAIDs-ASA, 59" /><sentence text="1 years) and highest for digoxin+verapamil (75"><entity charOffset="25-42" id="DDI-PubMed.24147143.s19.e0" text="digoxin+verapamil" /></sentence><sentence text="4 years)" /><sentence text=" In 13/27 pairs, the mean ages were ≥70 years" /><sentence text=" On average, subjects involved in pDDIs received ≥10 drugs" /><sentence text=" The odds of exposure were more frequently higher for age ≥65 years, males, and those taking a large number of drugs" /><sentence text=" A substantial number of clinically important pDDIs were observed, particularly among warfarin users" /><sentence text=" Awareness of the most prevalent pDDIs could help practitioners in preventing concomitant use, resulting in a better quality of drug prescription and potentially avoiding unwanted side effects" /><sentence text=" " /></document>